David Elsley
Fundador en CARDIOL THERAPEUTICS INC. .
Fortuna: 2 M $ al 30/04/2024
Cargos activos de David Elsley
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Director/Miembro de la Junta | 19/01/2017 | - |
Director Ejecutivo | 19/01/2017 | - | |
Fundador | 19/01/2017 | - | |
Presidente | 19/01/2017 | - |
Historial de carrera de David Elsley
Antiguos cargos conocidos de David Elsley.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Director/Miembro de la Junta | 01/01/1990 | 23/10/2009 |
Fundador | 01/01/1990 | 23/10/2009 |
Formación de David Elsley.
Richard Ivey School of Business | Masters Business Admin |
University of Western Ontario | Masters Business Admin |
Estadísticas
Internacional
Canadá | 5 |
Operativa
Director/Board Member | 2 |
Founder | 2 |
Masters Business Admin | 2 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
- Bolsa de valores
- Insiders
- David Elsley
- Experiencia